The pemetrexed-cisplatin chemotherapy is standard of care in first-line (FL) treatment of malignant pleural mesothelioma (MPM). The second-line (SL) chemotherapy is considered, but the optimal treatment has not been defined yet. The aim of this study was to evaluate the clinical outcomes of SL-therapy in a series of MPM-patients included in a retrospective multicenter database. Clinical records of MPM-patients who received SL-treatment from 1996 to 2008 were reviewed. Study endpoints were response, overall-survival (OS), and progression-free-survival (PFS) for SL, stratified for patient characteristics, FL-outcomes, and type of SL. Out of 423 patients, 181 with full clinical data were identified. Patients' characteristics: median-age 64 years (range: 36-85); male gender 115 (63.5%); good EORTC-score 109 (60.2%); epithelial histology 135 (74.6%). After FL, 147 (81.2%) patients achieved disease-control (DC) and 45 had a time-to-progression. ≥ 12. months (TTP. ≥ 12). After SL, 95 patients (52.6%) achieved DC (21 response; 74 stable-disease); median PFS and OS were 4.3 and 8.7. months, respectively. According to multivariate analysis, DC after SL-therapy was significantly related to pemetrexed-based treatment (OR: 2.46; p=. 0.017) and FL-TTP. ≥ 12 (OR: 3.50; p=. 0.006). PFS was related to younger age (<65. years) (HR: 0.70; p=. 0.045), ECOG-PS0 (HR: 0.67; p=. 0.022), and FL-TTP. ≥ 12 (HR: 0.45; p< 0.001). OS was significantly related to ECOG-PS0 (HR: 0.43; p< 0.001) and to FL-TTP. ≥ 12 (HR: 0.54; p=. 0.005). In pemetrexed pre-treated patients, re-treatment with a pemetrexed/platinum combination significantly reduced the risk-of-death than pemetrexed alone (HR: 0.11; p< 0.001). In conclusion, SL-chemotherapy seems to be active in MPM-patients, particularly in younger patients with ECOG-PS0 and prolonged TTP after FL-pemetrexed-based chemotherapy. In selected patients, re-challenge with pemetrexed-based regimens, preferentially associated with platinum-compound, appears to be an option for SL-setting.Considering the important limitations of this study, due to retrospective nature and the possible selection bias, prospective clinical trials are warranted to clarify these issues. © 2011 Elsevier Ireland Ltd.
Second-line chemotherapy in malignant pleural mesothelioma: Results of a retrospective multicenter survey / Zucali, P. A.; Simonelli, M.; Michetti, G.; Tiseo, M.; Ceresoli, G. L.; Collovà, E.; Follador, A.; Lo Dico, M.; Moretti, A.; De Vincenzo, F.; Lorenzi, E.; Perrino, M.; Giordano, L.; Farina, G.; Santoro, A.; Garassino, M.. - In: LUNG CANCER. - ISSN 0169-5002. - 75:3(2012), pp. 360-367. [10.1016/j.lungcan.2011.08.011]
Second-line chemotherapy in malignant pleural mesothelioma: Results of a retrospective multicenter survey
Tiseo, M.;
2012-01-01
Abstract
The pemetrexed-cisplatin chemotherapy is standard of care in first-line (FL) treatment of malignant pleural mesothelioma (MPM). The second-line (SL) chemotherapy is considered, but the optimal treatment has not been defined yet. The aim of this study was to evaluate the clinical outcomes of SL-therapy in a series of MPM-patients included in a retrospective multicenter database. Clinical records of MPM-patients who received SL-treatment from 1996 to 2008 were reviewed. Study endpoints were response, overall-survival (OS), and progression-free-survival (PFS) for SL, stratified for patient characteristics, FL-outcomes, and type of SL. Out of 423 patients, 181 with full clinical data were identified. Patients' characteristics: median-age 64 years (range: 36-85); male gender 115 (63.5%); good EORTC-score 109 (60.2%); epithelial histology 135 (74.6%). After FL, 147 (81.2%) patients achieved disease-control (DC) and 45 had a time-to-progression. ≥ 12. months (TTP. ≥ 12). After SL, 95 patients (52.6%) achieved DC (21 response; 74 stable-disease); median PFS and OS were 4.3 and 8.7. months, respectively. According to multivariate analysis, DC after SL-therapy was significantly related to pemetrexed-based treatment (OR: 2.46; p=. 0.017) and FL-TTP. ≥ 12 (OR: 3.50; p=. 0.006). PFS was related to younger age (<65. years) (HR: 0.70; p=. 0.045), ECOG-PS0 (HR: 0.67; p=. 0.022), and FL-TTP. ≥ 12 (HR: 0.45; p< 0.001). OS was significantly related to ECOG-PS0 (HR: 0.43; p< 0.001) and to FL-TTP. ≥ 12 (HR: 0.54; p=. 0.005). In pemetrexed pre-treated patients, re-treatment with a pemetrexed/platinum combination significantly reduced the risk-of-death than pemetrexed alone (HR: 0.11; p< 0.001). In conclusion, SL-chemotherapy seems to be active in MPM-patients, particularly in younger patients with ECOG-PS0 and prolonged TTP after FL-pemetrexed-based chemotherapy. In selected patients, re-challenge with pemetrexed-based regimens, preferentially associated with platinum-compound, appears to be an option for SL-setting.Considering the important limitations of this study, due to retrospective nature and the possible selection bias, prospective clinical trials are warranted to clarify these issues. © 2011 Elsevier Ireland Ltd.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
